Common Reasons for “For-Cause” Inspections in Bioequivalence Studies Submitted to the Food and Drug Administration
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 1
Abstract
“For-cause” inspections are initiated during the review of bioequivalence (BE) data submitted to Abbreviated New Drug Applications when possible scientific misconduct and study irregularities are discovered. We investigated the common reasons for initiating “for-cause” inspections related to the clinical, analytical, and dissolution study sites associated with BE studies. This information may help the pharmaceutical industry to understand the root causes of compliance failures in BE studies and help them to improve compliance with FDA’s regulations, thereby facilitating more rapid approval of safe and effective generic drugs.
Authors and Affiliations
Bing V. Li, Barbara M. Davit, Christina H. Lee, Santhosh K. Pabba, Chitra Mahadevan, Hoainhon T. Caramenico, Sam H Haidar, Aida L. Sanchez, Aaron W. Sigler, Ethan M. Stier, Dale P. Conner
Keywords
Related Articles
- EP ID EP681766
- DOI 10.1208/s12248-012-9415-9
- Views 81
- Downloads 0
Estimation of Biliary Excretion of Foreign Compounds Using Properties of Molecular Structure
The online version of this article (doi:10.1208/s12248-013-9541-z) contains supplementary material, which is available to authorized users.
Silica Colloidal Crystals as Emerging Materials for High-Throughput Protein Electrophoresis
Silica colloidal crystals are a new type of media for protein electrophoresis, and they are assessed for their promise in rapidly measuring aggregation of monoclonal antibodies. The nature of silica colloidal crystals is...
Immunogenicity of Subcutaneously Administered Therapeutic Proteins—a Mechanistic Perspective
The administration of therapeutic proteins via the subcutaneous route (sc) is desired for compliance and convenience, but could be challenging due to perceived immunogenic potential or unwanted immune responses. There ar...
Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape
The application of modeling and simulation techniques is increasingly common in preclinical stages of the drug discovery and development process. A survey focusing on preclinical pharmacokinetic/pharmacodynamics (PK/PD)...
Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9
The online version of this article (doi:10.1208/s12248-015-9750-8) contains supplementary material, which is available to authorized users.